Why the study?
Evidence that genetic variants determining clopidogrel on-treatment platelet inhibition have clinical utility to predict major adverse cardiovascular events remains controversial.
Does a pharmacogenomic polygenic response score predict major adverse cardiovascular events and cardiovascular mortality in clopidogrel-treated patients with coronary artery disease?
Population
3391 clopidogrel-treated CAD patients of the ICPC (2134 with clinical event data)
Comparison
Pharmacogenomic polygenic response score based on 31 candidate gene polymorphisms
Design
Cohort study
Authors
Loading...
Polygenic scores may refine clopidogrel response prediction; leaves open whether they improve outcomes or guide therapy.
Does a pharmacogenomic polygenic response score predict major adverse cardiovascular events and cardiovascular mortality in clopidogrel-treated patients with coronary artery disease?
A pharmacogenomic polygenic response score incorporating multiple genetic variants predicts ischemic events and cardiovascular mortality in clopidogrel-treated patients better than individual variants alone.
Lewis et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: